Tag archive for ‘Cubist’
Possible Impact of Merck Acqusition of Cubist on the Trius CVR
I was just asked about the potential impact on the value of the Trius CVR of the Merck acquisition of Cubist. You may recall that when Trius was acquired, Trius shareholders received $1.00 for each share that they tendered. If Syvestro (tedizolid) sales in the US, Europe and Canada reach $125 million in 2016 we get […]
Cubist Pharmaceuticals: An Overview Based on a Recent Company Presentation (CBST, No Opinion)
Introduction I recently was invited to attend a broker sponsored conference for biotechnology companies. Altogether, there were 116 companies presenting at the conference and I attended 29 individual company presentations. I regularly attend conferences like this to screen for potential new companies to cover and to get updates on companies that I already have done […]
Trius: Will there be a Higher Bidder and what is the CVR Worth? (TSRX; $14.10)
What is the CVR Worth? I wanted to address some additional points in regard to the proposed acquisition of Trius (TSRX) by Cubist (CBST). In my earlier note of July 31, I had not yet analyzed the terms of the CVR which are that Trius shareholders will receive $1.00 for each share that they tender […]
Trius Therapeutics to be Acquired by Cubist (TSRX: $13.66)
Implications for Trius Shareholders Cubist Pharmaceuticals (CBST) and Trius Therapeutics, Inc. (TSRX) announced that they have signed a definitive agreement under which Cubist will acquire all outstanding shares of Trius for $13.50 per share in cash. In addition, Trius shareholders will receive a Contingent Value Right that entitles Trius shareholders to receive up to $2.00 […]
Thoughts on the Growing Crisis of Bacterial Resistance to Antibiotics
Investment Overview We hear constantly from the media about problems with bacterial resistance to antibiotics. I think that this is an indication that we have reached the point at which society will collectively decide to declare a war on resistant bacteria that could provide the same impetus to the development of anti-microbial drugs that the […]
Trius’ (TSRX) Tedizolid Has Blockbuster Potential for MRSA Infections
Trius Therapeutics TSRX) is in late stage clinical development of its new antibiotic, tedizolid, for treatment of MRSA infections that have increased to epidemic levels in both the hospital and community settings. There are a number of companies competing in this market and a host of new products in development, but I see tedizolid as […]